Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises EQT Infrastructure II in connection with the Hector Rail group’s divestment of GB Railfreight (1)
Mandate

Vinge advises EQT Infrastructure II in connection with the Hector Rail group’s divestment of GB Railfreight

September 23, 2019 M&A

GB Railfreight was acquired by EQT Infrastructure II, through its current Swedish portfolio company Hector Rail, in November 2016 and is the third largest rail freight operator in the United Kingdom, with a turnover in excess of GBP 200m.

GB Railfreight is one of the fastest growing companies in the UK railway sector and transports goods and provides services for a wide range of customers.

 
Vinge has advised EQT Infrastructure II in connection with the restructuring of the Hector Rail group and in connection with the divestment of its UK subsidiary GB Railfreight. 
 
The transaction is expected to close mid‑October 2019.
 
Vinge’s team consisted of Daniel Rosvall, Karl Klackenberg, Hannes Pettersson and Milad Kamali. 
 

Related

Vinge advises Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of Bizware

 Vinge has advised the Nordic private equity firm Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of the data analytics and AI firm Bizware AB and its subsidiaries Bizware Lead AB and Bizware Nova AB.
September 11, 2025

Vinge has acted as local counsel supporting lead counsel Latham & Watkins in advising Cadence in connection with its acquisition of Hexagon’s Design & Engineering Business for approx. EUR 2.7 billion

 Cadence (Nasdaq: CDNS) announced it has entered into a definitive agreement to acquire the Design & Engineering business of Hexagon AB, which includes its MSC Software business—a pioneer in engineering simulation and analysis solutions.
September 09, 2025

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025